Taguchi, F., Solomon, B., Gregorc, V.. et al.: Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treat-ment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J. Natl. Cancer Inst.99(11): 838-846, 2007.
Van Cutsem, E., Lang, I., D’haens, G., et al.: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J. Clin. Oncol.26 (15S): 2, 2008.
Bokemeyer, C., Bondarenko, I., Hartmann, J. T., et al.: KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J. Clin. Oncol.26 (15S): 4000, 2008.
Kimura, H., Kasahara, K., Kawaishi, M., et al.: Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin. Cancer Res.12(13): 3915-3921, 2006.